Understanding and responding to COVID-19 in Wales: protocol for a privacy-protecting data platform for enhanced epidemiology and evaluation of interventionsPublic Health Published on 2020-10-212022-10-28 Journal: BMJ Open [Category] COVID-19, Fulltext, MERS, SARS, [키워드] Analysis approved clinical risk factor Cohort Complete COVID-19 COVID-19 pandemic dataset determine disease dissemination Epidemiology Ethics experiment Follow-up Governance group groups Health health informatics Health Service healthcare Infection influences on International Intervention morbidity and mortality Mortality National outcome outcomes Panel peer-reviewed platform populations Prevent protocol public health Rapid required Research review SARS-CoV-2 Spread subsequent Transmission understanding [DOI] 10.1136/bmjopen-2020-043010 PMC 바로가기 [Article Type] Public Health
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection – a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trialLetter Published on 2020-10-202022-10-29 Journal: Trials [Category] COVID-19, MERS, SARS, [키워드] 1:1 2019-nCoV allergic Antipyretic Antiretroviral therapy Antiviral Arm as required assigned Breastfeeding Care categories cause clinical combination therapy compassionate use cough country COVID-19 COVID-19 infection criteria death defined described discharged disease dissemination drug Efficacy element eligibility criteria enrolled enrolment Etiquette exclusion criteria exploratory female Fever Frequency H1N1 hand hygiene Hydration Hydroxychloroquine ICU Patients inclusion criteria India Infection infection with SARS-CoV-2 investigator Laboratory Loading dose Lopinavir/ritonavir Lopinavir/Ritonavir combination mechanical ventilation medication Mortality non-ICU non-invasive ventilation Non-severe case Normalisation number nutrition objective off-label organ oxygen saturation paO2/fiO2 participant Participants Patient pharmacotherapy Placebo positive Precaution progression protocol QT prolongation randomisation randomised randomised controlled trial randomization Randomized controlled trial Randomly receipt recruitment regimen Registration registry replaced required Research respiratory rate ribavirin RT-PCR Safety Sample size SARS-CoV-2 RT-PCR screened secondary secure Serious Adverse Event Severe COVID-19 Infection Severe patient severity specimen Standard standard treatment status stratified study period Study protocol supplemental oxygen Support Suppressant surgical sustained symptomatic patient Tablet tested the patient therapeutic intervention therapy time time to defervescence treated Treatment treatment arm treatment group Trial upper respiratory tract Vasopressor Ventilation ventilator wear website [DOI] 10.1186/s13063-020-04774-5 PMC 바로가기 [Article Type] Letter
Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and InhibitionMicrobiology Published on 2020-10-202022-10-31 Journal: Frontiers in Microbiology [Category] COVID-19, [키워드] affected Antiviral Apoptosis autophagy cascade change changes Community components COVID-19 death demonstrated detection diagnostics dissemination Endoplasmic reticulum Epidemiology Epigenetic event Genetic genetics and epigenetics global pandemic highlight host cell host’s immune response Inflammasome inhibition medications molecular mortality rate nanobased diagnosis nanobased therapeutics Nanotechnology outbreak Probability Prospective SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pathogenesis Scientific community Stress target cells the SARS-CoV-2 therapeutic options unfolded protein response UPR viral infection viral replication viral-induced Worldometer [DOI] 10.3389/fmicb.2020.02098 PMC 바로가기 [Article Type] Microbiology
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial이중 맹검, 무작위, 위약 대조 임상 3상 임상 시험을 통해 의료 전문가를 Sinovac에서 제조한 흡착된 COVID-19(불활성화) 백신으로 치료하는 효과와 안전성을 평가합니다. – PROFISCOV: 무작위 대조를 위한 연구 프로토콜의 구조화된 요약 재판Letter Published on 2020-10-152022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 95% confidence interval Active surveillance adjuvant Administered administration Adults adverse event adverse events Adverse reaction Adverse reactions age Aluminium aluminium hydroxide Analysis attack rate Beijing blind Blinding Brazil Breastfeeding calculated Care causal relationship China clinical clinical care clinically Committee completion confirmed case Consent consent form Contact contact with Control COVID-19 criterion database defined Diagnosis direct contact disease dissemination dose double-blind double-blind study Efficacy Efficacy and safety elderly element Endpoint evaluate exclusion criteria expected experimental intervention FDA form Frequency genders Health Health Organization hydroxide immunogenicity inactivated Inactivated Vaccines incidence include Inclusion information Informed intramuscular dose life limit Local monitoring multicenter nucleic acid number Nurse Nurses objective Occurrence Older outcome participant Participants Participation Patient phase Phase III Clinical Trial Placebo placebo-controlled clinical trial pregnant pregnant women primary efficacy endpoint produced product professional professionals protocol randomisation randomised randomised controlled trial randomization randomization list randomization system Randomized receive recruitment regimen registry responsible retained Safety Sample size SARS-CoV-2 nucleic acid SARS-CoV-2 virus schedule second vaccination separation Sinovac Sinovac Life Science Sinovac Life Sciences Sponsor status stratified Study protocol subjects symptomatic case symptomatic cases symptomatic individuals systemic adverse reaction systemic adverse reactions the vaccine threshold Trial Trial registration undergo vaccination Vaccine Virological voluntary website World Health Organization [DOI] 10.1186/s13063-020-04775-4 PMC 바로가기 [Article Type] Letter
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent [DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)증상이 있는 SARS-CoV-2 감염(COVID-19)이 있는 고령자의 가정 치료: 여러 가지 실험적 치료의 효능과 내약성을 평가하기 위한 MAMS(Multi-Arm Multi-Stage) 무작위 시험에 대한 연구 프로토콜의 구조화된 요약 65세 이상 외래 환자의 입원 또는 사망 위험 감소(COVERAGE 시험)Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 6-mercaptopurine Abnormalities ACEi added age amodiaquine Analysis antrafenine approved ARB ARBs Arm azathioprine Blinding Bordeaux Caregivers Chloroquine chronic hepatitis Chronic kidney disease citalopram clinical Colitis Combination comparator complex conducted Control control arm COVID-19 COVID-19 pandemic criteria CYP3A4 cytochrome P450 Dasatinib death Dementia dialysis dissemination Domperidone drug Duchy Efficacy element enrolled enrolment Enterocolitis escitalopram EudraCT Evidence exclusion criteria experimental arm experimental drug Experimental drugs Favipiravir feasibility Final final analysis first symptom first symptoms floctafenine France French futility galactose GFR glafenine Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase glucose-6-phosphate dehydrogenase deficiency Grand duchy halofantrine Health Insurance heart rate hepatic Hepatic porphyria home hospital hospitalisation Hydroxychloroquine hydroxyzine hypersensitivity Hyperuricemia Ileus Imatinib immunological incidence Inclusion increase in inducer inhibitor Interim analyses interim analysis intervals investigator investigators Isoenzyme Kidney disease Lactase Lactose liver failure Long Long QT syndrome Luxembourg malabsorption mefloquine mercaptopurine metabolism multi multi-arm nasopharyngeal Nasopharyngeal swab New Nilotinib not blinded number nursing home nursing homes objective Older Open-label open-label trial other treatment other treatments outcome Outpatient P450 Paris participant Patient performed phase Piperaquine Positive test Prevent primary care Primary outcome proportion protocol pyrazinamide QTc interval randomisation randomised Randomized Randomly receive recruited Region Registered regulatory authority repaglinide replaced REPLACED BY reported Repurposed drug residence Safety Monitoring Board Sample size SARS-CoV-2 SARS-COV-2 infection scale Stage Standard statistician statisticians status stratified Study protocol submitted symptomatic SARS-CoV-2 infection Tablet telmisartan tested theophylline Toxicity Trace element trace elements treated Treatment treatment arm Trial Trial registration Version virus Virus Disease Vitamin vitamins Warfarin [DOI] 10.1186/s13063-020-04619-1 PMC 바로가기 [Article Type] Letter
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-10-132022-10-29 Journal: Trials [Category] COVID-19, MERS, SARS, [키워드] 1:1 7-point ordinal scale adaptive Alfred Hospital allergy Antiviral Antiviral treatment Arm biomarkers of inflammation blinded to treatment childbearing potential clinical clinical benefit clinical symptom clinical trial Community Confirmed Contraception COVID-19 COVID-19 infection Day defined determine dialysis dissemination dose effective Efficacy element eligible enrolled enrolment Favipiravir female fertile GRADE hospitalisation hospitalised immune activation ineligible investigator male medication negative pregnancy test nucleic acid number objective outcome parallel-group participant Participants Patient performed Pharmacy Placebo protocol randomisation randomised randomised controlled trial recruit recruited recruitment renal impairment Sample size SARS-CoV-2 Screening secondary severe hepatic dysfunction Standard of care status stratified Study protocol study visit Swab Symptom the WHO time Treatment Trial triple-blind Victoria virological cure website [DOI] 10.1186/s13063-020-04766-5 PMC 바로가기 [Article Type] Letter
How is Brazil facing the crisis of Food and Nutrition Security during the COVID-19 pandemic?Commentary Published on 2020-10-122022-10-29 Journal: Public Health Nutrition [Category] Coronavirus, MERS, SARS, [키워드] activity Adequate Analysis Brazil carried community transmission COVID-19 COVID-19 pandemic Critical dissemination fertile food Food and Nutrition Security Government highlight Human Impact include individuals mechanism nutrition pandemic right School security urgency [DOI] 10.1017/S1368980020003973 PMC 바로가기 [Article Type] Commentary
Collective Response to Media Coverage of the COVID-19 Pandemic on Reddit and Wikipedia: Mixed-Methods AnalysisOriginal Paper Published on 2020-10-122022-10-30 Journal: Journal of Medical Internet Research [Category] COVID-19, MERS, SARS, [키워드] Affect Alter applied approach article Behavior Canada changes collected collective country Coverage COVID-19 COVID-19 incidence COVID-19 pandemic Data science Decline deviation digital epidemiology dissemination driven by Effect Epidemic Evolution health emergency heterogeneous infodemic infodemiology information infoveillance Italy Linear regression model media news coverage objective offer outbreak pandemic platform predict progression quantified question raise Reddit response Result Risk perception social media the disease The United States Topic topic modeling United Kingdom Wikipedia YouTube [DOI] 10.2196/21597 PMC 바로가기 [Article Type] Original Paper
Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trialLetter Published on 2020-10-092022-10-29 Journal: Trials [Category] Coronavirus, MERS, SARS, [키워드] 1:1 All study participants allergy antiarrhythmic drug anticipated Arm assigned Bandar Abbas blinded block randomization Breastfeeding C-reactive protein clinical clinical manifestation Clinical symptoms clinical trial Clinicians company Confirmed Control Corticosteroids COVID-19 criteria Critical Department Diagnosis disease Diseases disorder dissemination diuretics dose double-blind dry cough education Effect element Eligible participants exclusion criteria feature Features Fever GI symptom GI symptoms ginger history hypertension incidence Inclusion inhibitor investigator Iran liver lung involvement lymphocytopenia Ministry of Health number Nurses objective outcome parallel group participant Patient patients pharmaceutical placebo tablet placebo-controlled clinical trial Pneumonia polymerase chain Primary outcome protocol randomization Randomized Randomized controlled trial regimen Registered registration date registry renal Research respiratory Sample size SARS-CoV-2 secondary outcome selective Serious Adverse Event serotonin reuptake inhibitor Seven single center standard treatment status Study protocol Tablet therapeutic Thyroid time tiredness treatment arm two group Version web-based system website [DOI] 10.1186/s13063-020-04765-6 PMC 바로가기 [Article Type] Letter